Cargando…

A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma

BACKGROUND: Preclinical studies in mice have demonstrated that the prophylactic depletion of immunosuppressive regulatory T-cells (T(Regs)) through targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25) can enhance anti-tumor immunotherapy. However, therapeutic approaches are compli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampson, John H., Schmittling, Robert J., Archer, Gary E., Congdon, Kendra L., Nair, Smita K., Reap, Elizabeth A., Desjardins, Annick, Friedman, Allan H., Friedman, Henry S., Herndon, James E., Coan, April, McLendon, Roger E., Reardon, David A., Vredenburgh, James J., Bigner, Darell D., Mitchell, Duane A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288003/ https://www.ncbi.nlm.nih.gov/pubmed/22383993 http://dx.doi.org/10.1371/journal.pone.0031046

Ejemplares similares

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients
por: Mitchell, Duane A., et al.
Publicado: (2015)

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
por: Reardon, D A, et al.
Publicado: (2009)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Myeloablative Temozolomide Enhances CD8(+) T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice
por: Sanchez-Perez, Luis A., et al.
Publicado: (2013)

Current available therapies and future directions in the treatment of malignant gliomas
por: Desjardins, Annick, et al.
Publicado: (2009)

A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors
por: Kanaly, Charles W., et al.
Publicado: (2011)

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma
por: Miao, Hongsheng, et al.
Publicado: (2014)

IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2020)

The genetic landscape of anaplastic astrocytoma
por: Killela, Patrick J., et al.
Publicado: (2013)

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report
por: Peters, Katherine B., et al.
Publicado: (2010)

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy
por: Gromeier, Matthias, et al.
Publicado: (2021)

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
por: Kuan, Chien-Tsun, et al.
Publicado: (2010)

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016)

Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis
por: Kuan, Chien-Tsun, et al.
Publicado: (2010)

Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models
por: Bao, Xuhui, et al.
Publicado: (2013)

Monitoring Radiographic Brain Tumor Progression
por: Mehta, Ankit I., et al.
Publicado: (2011)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)

Informational needs assessment of non‐Hodgkin lymphoma survivors and their physicians
por: Friedman, Daphne R., et al.
Publicado: (2010)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014)

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas
por: Flores, Catherine, et al.
Publicado: (2015)

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Imaging of Convection Enhanced Delivery of Toxins in Humans
por: Mehta, Ankit I., et al.
Publicado: (2011)

A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope
por: Swartz, Adam M., et al.
Publicado: (2021)

Toxin-Based Targeted Therapy for Malignant Brain Tumors
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2012)

Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells()
por: Cui, Bo, et al.
Publicado: (2010)

A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system
por: Choi, Bryan D., et al.
Publicado: (2013)

KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation
por: Guo, Changcun, et al.
Publicado: (2013)

Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
por: Zhang, Liwei, et al.
Publicado: (2014)

Lymphopenia, Lymphopenia-Induced Proliferation, and Autoimmunity
por: Sheu, Ting-Ting, et al.
Publicado: (2021)

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
por: Diplas, Bill H., et al.
Publicado: (2018)

Intratumor childhood vaccine-specific CD4(+) T-cell recall coordinates antitumor CD8(+) T cells and eosinophils
por: Brown, Michael C, et al.
Publicado: (2023)

A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)

Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes
por: Duncan, Christopher G., et al.
Publicado: (2010)

Glioblastoma Stem Cells: A Neuropathologist's View
por: McLendon, Roger E., et al.
Publicado: (2011)

Electron transfer in inorganic, organic, and biological systems
por: Bolton, James R, et al.
Publicado: (1991)

Worsening of Lymphopenia during Apremilast Treatment
por: Kolios, Antonios G.A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_crlp3cf8hdpfc3aa2jc1j1gfch